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Abstract
Background: The involvement of xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer (PC)
and chronic fatigue syndrome (CFS) is disputed as its reported prevalence ranges from 0% to 25% in PC cases and
from 0% to more than 80% in CFS cases. To evaluate the risk of XMRV infection during blood transfusion in Japan,
we screened three populations–healthy donors (n = 500), patients with PC (n = 67), and patients with CFS (n =
100)–for antibodies against XMRV proteins in freshly collected blood samples. We also examined blood samples of
viral antibody-positive patients with PC and all (both antibody-positive and antibody-negative) patients with CFS
for XMRV DNA.
Results: Antibody screening by immunoblot analysis showed that a fraction of the cases (1.6-3.0%) possessed anti-
Gag antibodies regardless of their gender or disease condition. Most of these antibodies were highly specific to
XMRV Gag capsid protein, but none of the individuals in the three tested populations retained strong antibody
responses to multiple XMRV proteins. In the viral antibody-positive PC patients, we occasionally detected XMRV
genes in plasma and peripheral blood mononuclear cells but failed to isolate an infectious or full-length XMRV.
Further, all CFS patients tested negative for XMRV DNA in peripheral blood mononuclear cells.
Conclusion: Our data show no solid evidence of XMRV infection in any of the three populations tested, implying
that there is no association between the onset of PC or CFS and XMRV infection in Japan. However, the lack of
adequate human specimens as a positive control in Ab screening and the limited sample size do not allow us to
draw a firm conclusion.
Background
Xenotropic murine leukemia virus-related virus (XMRV),
a gammaretrovirus found in humans, is possibly associated
with certain diseases [1,2]. The virus was first identified in
prostate cancer (PC) by using a pan-viral microarray;
XMRV RNA was detected in eight of 22 R462Q homozy-
gous patients, but in only one of 66 patients with RQ or
RR (wild-type [WT]) alleles of the RNASEL gene [1], an
important component of the innate antiviral response [3].
Schlaberg et al. [4] found XMRV proteins in nearly 25% of
PC specimens and reported that XMRV infection is asso-
ciated with high-grade PC. Conversely, XMRV RNA was
detected in only 1.2% of PC cases in a German study [5],
and neither XMRV RNA nor anti-XMRV antibodies (Abs)
were detected in PC patients in another German cohort
[6]. Furthermore, in a recent study, XMRV RNA was
detected in the blood of 67% of patients with chronic fati-
gue syndrome (CFS) and 3.6% of healthy individuals [2].
Lo et al. [7] found murine leukemia virus (MLV)-related
sequences in genomic DNA of peripheral blood mononuc-
l e a rc e l l s( P B M C s )i n3 2o f3 7( 8 6 . 5 % )C F Sp a t i e n t sa n d
three of 44 (6.8%) healthy blood donors. However, the
absence of XMRV infection in CFS patients has been
reported in several countries [8-12]. These conflicting
results have provoked serious debates about XMRV detec-
tion methods and patient characteristics [13].
XMRV can infect many human cell lines by using
XPR1 as a receptor, similar to other xenotropic murine
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be enhanced in cells with a defective interferon-gamma
(IFNg) intracellular pathway [17]. In terms of in vivo
infection, the route of transmission, infectivity to
humans, and pathogenesis of XMRV are largely
unknown; therefore, its potential risk as a transfusion-
transmissible infectious agent remains to be clarified.
Many blood service organizations worldwide, including
those in Japan, have yet to establish a transfusion policy
for XMRV, although in a few countries (e.g., Canada)
blood donations are restrict e df r o mi n d i v i d u a l sp r e -
viously diagnosed with CFS. To investigate the preva-
lence of XMRV in healthy Japanese individuals as well as
in PC patients, we started screening blood samples in
2007 from donors in Osaka prefecture and PC patients in
Nishiwaki City, a rural area of Hyogo prefecture close to
Osaka prefecture, as a pilot study of XMRV infection. On
the basis of Lombardi et al.’s results of XMRV infection
in CSF patients and, to a lesser extent, in the healthy
population [2], we also screened blood samples from CFS
patients. We found that a proportion of the donors and
patients had Abs against the XMRV Gag capsid (CA),
but XMRV genes were barely detectable. These results
suggest that although the presence of human infection
with XMRV or XMRV-related viruses in Japan cannot be
denied, such infection is likely to be limited.
Results
Study design
Our study design, summarized in Figure 1, was not
standardized because the screening process for donors
and PC patients was not implemented simultaneously
with that for CFS patients. We employed different meth-
ods to detect XMRV nucleic acids at different stages of
the study, but the same Ab-screening test was used con-
sistently throughout. All plasma samples were screened
for XMRV Abs by immunoblot assay to calculate the
serological prevalence of XMRV. Plasma samples of viral
Ab-positive PC patients were further screened for
XMRV RNA. Moreover, PBMCs of PC patients whose
plasma was positive for XMRV RNA were examined for
t h ep r e s e n c eo fX M R Vg e n e sa n df o rRNASEL muta-
tions in genomic DNA [1,18]. Plasma samples of CFS
patients were simultaneously screened for XMRV Abs
and genomic DNA according to published methods
[1,2,6]. We did not examine XMRV DNA or RNA in
the donor blood samples because, at present, the Japa-
nese Red Cross Society does not have consensus for the
genetic analysis of donor blood samples for research
purposes, except for the analysis of blood types.
Screening for XMRV Abs
To examine Abs against XMRV by immunoblotting,
concentrated viral particles were used as antigens.
When the same volume of XMRV and human immuno-
deficiency virus (HIV)-1 lysate as a negative control was
analyzed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and gel staining, we
observed a comparable amount of Gag CA proteins in
each preparation (Figure 2A, asterisks). The minimum
amount of each virus lysate in which CA protein was
detectable by gel staining with SYPRO ruby (3 μl) was
used to assess sensitivity of the immunoblot assay by
end point dilutions of an anti-Gag monoclonal antibody
(mAb) (clone R187; Figure 2B, left) or an anti-Env rabbit
polyclonal antibody (pAb) (Figure 2B, right). The detec-
tion limit of the screening assay was estimated as 6.3
ng/ml (1:640,000) for R187 mAb and 1.1 μg/ml (1:8,000)
for anti-Env pAb.
In the Ab screening, we observed many nonspecific
signals. Most of these reacted with both strips at the
same mobility, and some weak bands were occasionally
detected on either XMRV or HIV-1, or both strips at
the position of the CA proteins, probably because of a
large amount of CA protein on the strips. Therefore, we
regarded such nonspecific signals as false positives, and
considered that a band observed on the XMRV strip,
but not on the HIV-1 strip, showing signal intensity
comparable with that detected using the control anti-
Gag mAb was positive for XMRV when the strips were
blotted with 100 times-diluted plasma samples (red
squares in Figure 2C-E). We identified 12 positive
plasma samples: eight from the donors, two from PC
patients and two from CFS patients. The prevalence of
XMRV calculated from the immunoblot assay was 1.6%
If positive 
Serological Prevalence 
Randomized Blood Donors 
N=500 (2007-2009) 
Prostate Cancer Patients 
N=67(2007-2009) 
If positive 
CFS Patients 
N=100 (2010) 
Prevalence of 
carrier 
          Antibody screening by Immunoblot analysis 
Genomic 
PCR  
of PBMC  Detection of viral DNA/RNA 
Mutation in RNaseL 
Figure 1 Study flowchart. Plasma samples randomly collected
from 500 healthy donors, 67 PC patients and 100 CFS patients were
screened for XMRV Abs in an immunoblot assay to estimate the
serological prevalence of the virus. Viral Ab-positive PC patients
were further tested for the presence of viral RNA in their plasma;
genomic DNA from PBMCs of XMRV RNA-positive patients was also
tested for viral DNA and RNaseL mutations. CSF patients were
screened by genomic PCRs at three independent laboratories.
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Page 2 of 12in blood donors, 3.0% in PC patients, and 2.0% in CFS
patients (p > 0.05). Because XMRV was originally identi-
fied in PC samples [1], we analyzed whether there was a
gender difference in the prevalence of XMRV; however,
no significant difference between male and female sub-
jects was noted (Table 1).
Characterization of screening-positive Abs
Because we observed Abs against only the Gag CA pro-
tein in the Ab-screening assay, we examined test plasma
for reactivity against recombinant Gag and Env proteins
(Figure 3A-3C). For recombinant Gag protein, we
expressed glutathione S transferase (GST)-fused Gag CA
protein of XMRV derived from 22Rv1 cells. The sensi-
tivity of the immunoblot assay using the GST-CA pro-
tein was about eight times higher than that used in the
screening assay (Figure 3A, 1:5,120,000 dilution corre-
sponding to 0.78 ng/ml R187 mAb). All screening-posi-
tive plasma, but not screening-negative plasma, tested
positive for GST-CA proteins (Figure 3B), suggesting
that the screening-positive plasma specifically recog-
nized XMRV CA. In the upper panel of Figure 3B, D51,
P24 and C32, plasma shows some signals migrating
close to that of the Env surface subunit (SU). However,
these were likely to be nonspecific as we observed simi-
lar signals on the paired HIV strip at the same position
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Figure 2 XMRV Ab screening. Immunoblot assay of proteins of HIV-1 Env-defective mutant (HIV Δenv) and XMRV clone VP62 for screening
anti-XMRV antibodies in plasma. (A) Three different amounts of viral preparations (3, 6, or 9 μl/lane indicated by black triangles) were separated
by 5-20% SDS-PAGE and stained with SYPRO Ruby. Asterisks represent Gag capsid (CA) proteins: *p24 in HIV and **p30 in XMRV. (B) Sensitivity of
immunoblot assay used for screening. Viral lysates (3 μl) were detected with serially diluted control antibodies. An anti-spleen focus-forming virus
(SFFV) Gag mAb (clone R187, left) and anti-XMRV Env pAb (right) was used for detection of Gag or Env proteins. Concentrations of detecting
limit of each antibody were 6.3 ng/ml (1:640,000) in R187 mAb and 1.1 μg/ml (1:8,000) in anti-Env pAb. H, HIVΔenv; X, XMRV; CA, Gag capsid; SU,
Env surface subunit; TM, Env transmembrane subunit. (C-E) Ab screening by immunoblot assay of blood donor samples (C), PC patients (D), and
CFS patients (E) using 3 μl of each viral lysate. Pairs of strips were incubated with 1:100 diluted plasma from individuals. XMRV-specific reactivity
of substantial intensity was defined as a positive reaction (red squares).
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D51, and Figure 2D and 2E for P24 and C32, respec-
tively). We examined the reactivity of the test plasma
against a recombinant histidine-tagged Env surface sub-
unit protein (rSU) of a xenotropic MLV [19], in which
the detection limit determined by endpoint dilutions
was 1.1 μg/ml (1:8,000 dilution in Figure 3C, left), but
detected no Abs against the Env SU protein in plasma
samples (Figure 3C, right). An immunoblot assay after
native-PAGE was also negative for Abs against Env pro-
teins (Figure 3D). Detection limits in the native-PAGE
were 6.3 ng/ml for anti-Gag mAb (R187) and 8.5 μg/ml
for anti-Env pAb (data not shown).
To examine the specificity of the screening-positive
plasma samples, we performed an additional immuno-
blot assay against proteins from Moloney murine leuke-
mia virus (MoMLV), which has approximately 83%
amino acid homology in the Gag region with XMRV.
We observed multiple patterns of cross-reactivity (Fig-
ure 3E). Most screening-positive plasma samples were
recognized exclusively with XMRV Gag CA (e.g., patient
24 in Figure 3E), but some showed weak cross-reactivity
with Gag CA of MoMLV (donor 359 in Figure 3E). In
another case, almost the same level of signal was
detected against Gag CA of XMRV and MoMLV (donor
385 in Figure 3E). Plasma that predominantly reacted
with MoMLV Gag was not observed. The Ab specifici-
ties are summarized in Table 2.
The serological prevalence of XMRV calculated using
only the highly specific Ab was 1.0% in the donors, 1.5%
in PC patients, and 1.0% in CFS patients. Again, there
were no statistically significant differences in prevalence
between blood donors and patients with either PC or
CFS. We are unable to determine whether the anti-Gag
CA Abs we identified would indicate XMRV infection
or not, until panel plasma or serum samples collected
from human subjects definitely infected with XMRV
become available. Therefore, we tentatively regard those
individuals who retain these Abs as suspicious cases.
Detection of XMRV RNA in the plasma of PC patients
In April 2008, we examined XMRV RNA from the
plasma of two screening-positive PC patients (P24 and
P28) by nested RT-PCR: only one patient (P24) had
positive results for XMRV RNA with Gag-specific pri-
mers (Figure 4A). The sequence of the amplified PCR
product was 99.8% (412/413), identical to that of XMRV
VP62 (data not shown). However, we could not con-
clude that the PCR product was derived from XMRV
infection because this fragment did not contain an
XMRV-specific 24 nucleotide deletion in the gag region
[1]. The patient’s malignant prostate tissue was not
available because it had already been removed and was
not deposited in the hospital.
In August 2008, we collected whole blood from this
patient to examine RNASEL mutations at amino acid
positions 462 [1,18] and 541 [20], and found a WT resi-
due at 462 and a low-risk amino acid residue (Glu) at
541 (data not shown). We tried to isolate infectious or
full-length XMRV from PBMCs of this patient, but were
unsuccessful. We also found that the test results of the
nested PCR assay, in which detection limit was approxi-
mately 1.5 cell equivalents of genomic DNA from 293T
cells infected with 22Rv1 cell-derived XMRV (Figure
4B), using PBMC-extracted genomic DNA were not
reproducible (Figure 4C). In November 2009, the whole
blood of P24 became available again and was tested for
XMRV DNA and RNA. Although the plasma still tested
positive for Abs against XMRV Gag CA, neither XMRV
RNA nor DNA was detected with the same method
used in April 2008 (data not shown). We further exam-
ined XMRV RNA from plasma and supernatants of co-
cultured P24 PBMCs with LNCap-FGC cells using one-
step RT-PCR, but both tested negative for the XMRV
Gag gene (Figure 5A). We performed real time PCR on
genomic DNA extracted from PBMCs, which is capable
of amplifying a fragment of the Env gene with a detec-
tion limit of four copies/reaction, but the additional
PCR tests of P24 were negative for the XMRV gene
(Figure 5B and 5C). These data suggested that the
amount of XMRV in the blood of the Ab-positive PC
patient was limited, if the virus still existed. Alterna-
tively, it remains possible that the results of the original
P24 PCR tests were false positive.
Detection of XMRV DNA in PBMCs of CFS patients
To examine the prevalence of XMRV in CFS cases, we
screened CFS patients for XMRV DNA in PBMCs at
three independent laboratories. Figure 6 shows the
representative results with two primer sets. The
Table 1 Summary of anti-Gag Ab reactivities in study
population
Population Gender Ab
negative
Ab
positive
Total Prevalence
(%)
Healthy
donors
M 336 5 341 1.5
F 156 3 159 1.9
Total 492 8 500 1.6
Patients with
PC
M 65 2 67 3.0
Patients with
CFS
M 31 0 31 0
F 67 2 69 2.9
Total 98 2 100 2.0
No significant differences in prevalence were observed between the donors
and the patients with PC and between the donors and the patients with CFS.
Further, there were no significant differences in prevalence between the male
and the female donors.
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Figure 3 Characterization of Gag CA-positive plasma samples. (A) Sensitivity of immunoblot assay with GST-fused recombinant Gag CA
(GST-CA) protein. GST-CA protein (300 ng per lane) was analyzed by 5-20% SDS-PAGE and detected with serially diluted R187 anti-Gag mAb.
The concentration of the detection limit was 0.78 ng/ml (1:5,120,000). (B) Immunoblot assay of plasma samples that tested positive (D7, D20,
D51, D98, D183, D184, D359, D385 in blood donors; P24 and P28 in PC patients; C4 and C32 in CFS patients) or negative (D306 and D307 in
blood donors) for the screening immunoblot assay with 3 μl of VP62 virus lysate (upper panel) or 300 ng of the GST-CA recombinant protein
(lower panel). For positive control, 8.5 μg/mL (1:1,000) of anti-Env pAb and 0.8 μg/ml (1:5,000) of anti-Gag mAb, R187, were used. (C)
Immunoblot assay using recombinant Env SU (rSU) protein of xenotropic MLV. The detection limit of 300 ng of rSU protein was 1.1 μg/ml
(1:8,000) by anti-Env pAb (left). One hundred diluted plasma samples tested positive for the screening assay were negative for rSU protein (right).
(D) Immunoblot assay in a native-PAGE using 5 μl of the concentrated VP62 lysate in native sample buffer. Plasma samples testing positive (D7
to C32) and negative (D306 and 307) for the screening assay were examined. a-Env, anti-Env pAb (1:200, 42.5 μg/ml); a-Gag, R187 mAb
(1:80,000, 50 ng/ml). (E) MoMLV particles with (M) or without (M’) amphotropic Env were produced and subjected to an immunoblot assay to
examine their cross-reactivity with XMRV-positive plasma. PC, a mixture of anti-Gag mAb (R187, 0.4 μg/ml) and anti-Env pAb (8.5 μg/ml) as the
positive control. Arrow head, GST-fused Gag Capsid protein; SU, Env surface subunit; rSU, recombinant Env surface subunit of xenotropic MLV;
TM, Env TM subunit; CA, Gag capsid protein.
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Page 5 of 12sensitivities of our PCR tests with primer sets indicated
in Figure 6A were determined using genomic DNA
extracted from 293T cells infected with 22Rv1 cell-
derived XMRV (Figure 6B and 6C). The detection limit
of both PCR tests was calculated as approximately 1.5
cell equivalents of genomic DNA from 293T cells
infected with 22Rv1 cell-derived XMRV. In screening
PCR tests, we observed several nonspecific bands but
the XMRV gene was not amplified as shown in Figure
6D. Although bands of a similar size to that expected
were occasionally observed, sequencing analysis indi-
cated that they contained human genomic DNA rather
than XMRV genes (data not shown).
In the Japanese Red Cross Osaka Blood Center, we
performed nested RT-PCR analysis of the gag region
by using plasma RNA (Figure 5A), and a real-time
TaqMan PCR assay of genomic DNA to amplify the
env region (data not shown) if the patients tested posi-
tive for Abs. We observed no positive results from the
PCR assays performed at the three independent labora-
tories or this additional PCR test, indicating that there
were no detectable amounts of XMRV DNA in the
blood of CFS patients, although two of 100 patients
tested positive for the XMRV Gag Ab (Figure 2E, 3B,
and 3D, and Table 1).
Discussion
In this study, we identified a small number of people
who possessed Abs against XMRV Gag CA, regardless
of gender or disease condition (PC and CFS), but none
of the individuals in the three tested populations
retained strong Ab responses to multiple XMRV pro-
teins. We were unable to isolate XMRV from the blood
of PC patients and detected no XMRV genes in the
blood of any CFS patients.
We screened blood donors and patients with PC and
CFS for XMRV Abs using a similar method to that
developed as our in-house confirmatory test for human
T-lymphotropic virus (HTLV)-1 infection in Japanese
blood donors in the late 1980s, as no XMRV-positive
human plasma was available to validate XMRV Ab tests.
Table 2 Cross-reactivities with MoMLV proteins
Population (-) (+)
Healthy donors 5 3
Patients with PC* 1
Patients with CFS 1 1
Total 7 4
The XMRV Ab-positive cases were categorized as having (+) or not having (-)
cross-reactivities with Gag proteins of MoMLV.
*Cross-reactivity was not examined in one Ab-positive patient with PC (P28)
because additional plasma from this patient was not available.
A 
N HV p24 PC M
Nested PCR Nested PCR PCR with  
inner primer
N HV p24 PC M
C 
Nested PCR
24nt deletion 
Gag  Gly-Gag 
GAG-O/I-F GAG-O/I-R 
Plasma RT-PCR 
500 
300 
N P24 P28 M
400 
650 
Nested PCR
M 105 HV N 104103 102 101 100 10-1 0
DNA of infected 293T cells
DNA of 105 293T cells B
Figure 4 Detection of XMRV genes from viral Ab-positive PC patients. (A) Primer positions used in the PCR assay (upper panel). Gly-Gag;
homologous region to glycosylated Gag of MLVs at the NH2 terminus of Gag. RNAs purified from the plasma of viral Ab-positive PC patients
(P24 and P28) were used in a nested RT-PCR with primers GAG-O-F/R and GAG-I-F/R. Unnecessary lanes between the negative control without
template RNA (N) and P24 have been removed from the original image (lower panel). (B) The detection limit of nested genomic PCR. Genomic
DNA extracted from serially diluted 293T cells infected with 22Rv1 cell-derived XMRV (indicated as 10
5~0) was mixed with genomic DNA
extracted from 10
5 293T cells. For one reaction of PCR with a volume of 20 μl, 100 ng of each DNA mixture was used. The final concentration of
viral genome contained in a PCR reaction was calculated as 7610.5-0.152 cell equivalents of genomic DNA from 293T cells infected with 22Rv1
cell-derived XMRV (corresponding to the lanes indicated as 10
5-10
-1 of infected 293T cells). The detection limit of the nested PCR was calculated
as approximately 1.5 cell equivalents (indicated as “10
1“). (C) Inconsistent results of nested genomic PCR tests for XMRV using genomic DNA
extracted from PBMCs. In a 20 μL volume, 100 ng genomic DNA were used for amplification. Nested genomic PCRs were performed on
September 17 (left) and September 18 (right), 2008. M, molecular size marker; N, negative control without nucleic acids; P24 and P28, nucleic
acids purified from PBMCs of P24 or P28; HV, genomic DNA of healthy volunteer; PC, diluted XMRV VP62 plasmid; arrow head, amplified band
using inner primer pair.
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Page 6 of 12Unlike HTLV and HIV infection, XMRV-positive plasma
bound only to Gag CA proteins in our study. However,
in feline gammaretrovirus infections, immune responses
are not always strong enough to induce a detectable
amount of Abs [21]. In an animal study of XMRV infec-
tion, Qiu and colleagues [22] found that rhesus maca-
ques intravenously inoculated with 3.6 ×10
6 50% tissue
culture infective dose of XMRV showed good Ab
responses against Env SU, Env transmembrane subunit
(TM), and Gag proteins. In this animal model, transient
viremia was observed for less than 2 weeks, but the Ab
responses prolonged over 100 days post-inoculation and
declined thereafter without boosting, despite high-dose
viral inoculation [22]. These data suggest that XMRV
replication is relatively limited in vivo to induce lasting
immune responses compared with HIV and HTLV
infection. Alternatively, the anti-Gag CA Abs we
observed could account for cross-reactivity with other
immunogens, although seven of 11 Ab-positive plasma
samples showed high specificity to XMRV Gag (Figure
3E and Table 2). In addition, Western blotting of 2262
blood donors by Qiu and colleagues identified two
blood donors positive for anti-p30 (CA) Ab and one
positive for anti-gp70 (Env SU) [22]. These Ab-positive
blood donors showed no multiple reactivities to viral
antigens, as observed in the present study, but the pre-
valence of the single antigen-reactive donor was much
lower than that in our current result (0.13% vs. 1.6%,
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RNA
Figure 5 Detection of XMRV RNA and DNA in viral Ab-positive samples. (A) RNA was purified from 1 mL of coculture supernatant of
activated PBMCs and LNCap-FGC cells (lane 2) or 1 ml plasma (lanes 3-6). For one-step RT-PCR, 15 μlo f6 0μl eluted RNA was amplified in a 25
μl volume. CFS patients C4 and C32 tested positive for XMRV Abs but C1 was negative. (B) Detection of XMRV env by TaqMan real-time PCR
assay. Duplicated test samples of diluted XMRV plasmid (VP62) were amplified. The detection limit of the TaqMan real-time PCR was 4 copies/
reaction determined by VP62 plasmid. (C) Duplicated test samples without template DNA in negative control (N) or with genomic DNA
extracted from PBMCs of a viral Ab-positive PC patient (P24) and healthy volunteers (HV) were amplified as for (B).
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CA protein might include more cross-reactivity in our
study. Further investigation of human plasma collected
from individuals clearly infected with XMRV is required
to verify our Ab screening results.
At the beginning of our study, the presence of XMRV
in the blood of PC patients had not been reported; how-
ever, we speculated that XMRV might infect blood cells
similar to the infection of PBMCs by other gammaretro-
viruses [23]. We obtained positive nested RT-PCR
results on plasma collected from the Ab-positive PC
patient only with extensive PCR conditions of 50 cycles
using outer and inner primer pairs (Figure 4A, P24). We
were, however, unable to consistently detect the XMRV
gene in the same patient 4 and 15 months later using
freshly collected blood samples. Co-cultivation of acti-
vated PBMCs by Concanavalin A and IL-2 with the
LNCap-FGC cell line, which is highly susceptible to
XMRV [17], gave rise to devastating LNCap-FGC cell
death (data not shown), and we were unable to detect
XMRV genes in the cell culture (Figure 5A). Our data
suggest that P24 was perhaps infected with XMRV or
some related viruses, but viral replication in the blood
was somewhat limited. If this is the case, the prevalence
of XMRV in PC patients (one of 67 patients) would be
relatively close to that previously reported [5]. We can-
not, however, exclude the possibility that the positive
P24 signal in the PCR assays was caused by contamina-
tion, as discussed recently [24-26]. We did not PCR-
amplify mouse-derived genetic materials [24,25] because
of the lack of remaining P24 test sample that tested
positive for XMRV PCR, although we did use a hot start
Taq polymerase that is inactivated not by anti-Taq
mouse mAbs but by chemical modification in our RT-
PCR test [26].
We were unable to detect XMRV DNA or RNA in
CFS patients, in accordance with the results of some
previous studies [8-12]. It is unlikely that our detection
A  B 
D 
DNA of infected 293T cells 
DNA of 105 293T cells 
500
1000
M 105 104 103 102 101 100 10-1 0 N
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C 
N
X
M
R
V
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300
736 
bp
99 bp
225 bp
M N 45 46 47 48 49 50 51 52 53 54 55 56 U P
736 bp
CFS patient
99 bp
HV
24nt deletion 
In-For 363  Del-Rev 461 
419F  1154R 
Gag  Gly-Gag 
GAPDH
Figure 6 Screening of CFS patients using genomic PCR. (A) Primer positions used in the PCR assay. Gly-Gag; homologous region to
glycosylated Gag of MLVs at the NH2 terminus of Gag. The detection limits of the genomic PCR assays with primers 419F and 1154R, and In-For
363 and Del-Rev 461 are shown in (B) and (C), respectively. Genomic DNA extracted from serially diluted 293T cells infected with 22Rv1 cell-derived
XMRV was mixed with genomic DNA extracted from 1.0 × 10
5 293T cells. For one reaction with a volume of 20 μl, 100 ng of each DNA mixture was
used. The final concentration of the detected viral genome was calculated as 7610.5-0.152 copies (corresponding to the lanes of 10
5-10
-1 infected
293T cells, respectively) in a reaction. The detection limit of both PCR tests is approximately 1.5 cell equivalents of genomic DNA from 293T cells
infected with 22Rv1 cell-derived XMRV indicated as “10
1“of infected 293T cells. (D) Representative results of PCR assay with primers indicated in (B)
(upper) and (C) (middle). The human GAPDH gene was examined as an internal control (bottom). M, molecular size marker; HV, genomic DNA of
healthy volunteers; N, no template; U, genomic DNA of uninfected 293T cells; P, genomic DNA of infected 293T cells.
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dies that reported a prevalence of 67% or 86.5% [2,7],
because all studies employed highly sensitive PCR meth-
ods. The difference may instead be explained by the
characteristics of patient populations. All CFS patients
in our study met the Centers of Disease Control and
Prevention (CDC) diagnostic criteria [27]; however, the
currently employed diagnosis of CFS is not based on
objective and quantitative measures but on the claims of
patients and some authorized criteria.
Although our results of Ab screening are ambiguous,
we conclude that XMRV infection is not involved in the
onset and/or progression of PC and CFS in the popula-
tion we screened. Even if the Abs we detected, or at
least the XMRV-specific ones, were caused by XMRV
infection, there was no statistically significant difference
in the serological prevalence of XMRV among the three
populations of the study. Moreover, the negative or
inconsistent PCR results in the Ab-positive patients can
be explained by the limited replication of XMRV in
vivo. Alternatively, by assuming that the Ab reaction is
attributable to cross-reactivity, the negative PCR results
likely indicate the absence of XMRV infection in
patients. In either case, our results do not support an
association between XMRV and CFS, in line with pre-
vious findings [8-12].
Retroviral integration is theoretically harmful to the
host cell because it disrupts the host genome. To reduce
the risk of XMRV infection during blood transfusion, a
r e l i a b l es c r e e n i n gs t r a t e g ys h o u l db ee s t a b l i s h e d .T h e
implementation of such a screening or inactivation pro-
tocol for blood products, however, will be influenced by
the evaluation of the prevalence of XMRV by a universal
test with high sensitivity and specificity, which must be
urgently developed.
Conclusions
Our data for Japanese blood donors, PC patients and
CFS patients imply that there is no association between
the onset of PC or CFS and XMRV infection, although
the lack of adequate human specimens as a positive
control and the limited sample size do not allow us to
draw an ultimate conclusion.
Methods
Sample collection
Plasma samples randomly collected from healthy donors
(n = 500) at the Japanese Red Cross Osaka Blood Center
between December 2006 and May 2009 were subjected
to XMRV Ab screening. All donors had negative results
in the routine tests at the Center: antigen testing of
hepatitis B virus (HBV) and human parvovirus B19; Ab
testing against HBV, hepatitis C virus (HCV), HIV-1,
HIV-2, HTLV-1, and syphilis; nucleic acids of HIV-1,
HIV-2, HBV, and HCV. All procedures in the donor
screening study were performed according to the guide-
lines of the Japanese Red Cross Society, which do not
permit the detection of nucleic acids from unapproved
viruses.
All patients with PC enrolled in this study (n = 67)
received medical treatment at Nishiwaki City Hospital
(Hyogo Prefecture, Japan) between December 2007 and
December 2009, when plasma samples were collected,
and provided written informed consent. Whole blood
samples in ethylenediaminetetraacetic acid (EDTA) were
separated by centrifugation, and the plasma was stored
at -80°C until use. PBMCs of the patients who tested
positive for XMRV Abs and RNA were used for RNA-
SEL sequencing and viral isolation. This study was
approved by the ethical committee of Nishiwaki City
Hospital.
CFS patients in this study fulfilled the 1994 CDC
Fukuda criteria [27] and received medical treatment at
the Fatigue Clinic Center, Osaka City University Gradu-
ate School of Medicine, Osaka, Japan between April and
August 2010. Most of the patients were female (69%)
with an age distribution of 17-62 years (mean, 38 years).
The mean interval from disease onset to blood collec-
tion was 126.5 months (11-337 months). Duplicated
tubes of 4 ml of whole blood in EDTA were used for
Ab screening and genomic PCR assay. Whole blood
samples were also collected into sodium heparin tubes
(Becton Dickinson, Franklin Lakes, NJ) for cell culture.
All blood samples were conveyed to the Japanese Red
Cross Osaka Blood Center and genomic DNA was puri-
fied from them on the same day. Three aliquots of
genomic DNA purified from one patient were indepen-
dently analyzed at three laboratories. This study was
approved by the Ethics Committee of Osaka City Uni-
versity Graduate School of Medicine and all blood sam-
ples were collected with written informed consent.
Cell lines and culture
Human 293T and 22Rv1 cells were obtained from the
American Type Culture Collection (CRL-1537 and CRL-
2525, respectively; ATCC, Manassas, VA). Human pros-
tate cancer cell line LNCap-FGC was obtained from the
RIKEN Cell Bank (Tukuba, Japan), and the GP293
packaging cell line was purchased from Clontech
Laboratories (Mountain View, CA). These cells were
grown in Dulbecco’s modified essential medium supple-
mented with 10% fetal bovine serum (FBS) and antibio-
tics. Rat hybridoma cell line R187 was obtained from
ATCC (CRL-1912) and maintained in RPMI-1640 med-
ium supplemented with 50 nM 2-mercaptoethanol, 10%
FBS, and antibiotics. Before collecting the culture super-
natant, the growth medium was replaced with CD
Hybridoma medium (Invitrogen, Carlsbad, CA)
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Env production, Sf9 and High Five cells (Invitrogen)
were maintained in Sf-900 III SFM and Expressed Five
medium (Invitrogen), respectively.
Control antibodies
IgG proteins in culture supernatants from R187 cells,
prepared against SFFV Gag and able to react with Gag
capsid proteins from a wide variety of gammaretro-
viruses [28], were purified using a protein G affinity col-
umn (MabTrap Kit; Amersham Biosciences, Piscataway,
NJ). For anti-Env Abs, rabbits were immunized with a
mixture of two peptides (PRVPIGPNPV[C] of Env SU
and [C]QFEQLAAIHTDLG of Env TM; [C] indicates an
additional cysteine residue for peptide purification), and
their antisera were collected and purified after five
immunization steps with a Protein A affinity column
( G EH e a l t h c a r e ,B u c k i n g h a m s h i r e ,U K ) .C o n c e n t r a t i o n s
of the purified R187 mAb and anti-Env pAb were 4.0
mg/ml and 8.5 mg/ml, respectively.
Antibody screening
An infectious XMRV molecular clone, pcDNA3.1-VP62,
was provided by Dr. R. H. Silverman. To produce the
viral particles, 293T cells were transfected with
pcDNA3.1-VP62 by a liposome method (Lipofectamine
LTX; Invitrogen). Two days after transfection, the cul-
ture supernatant was collected, filtered, and concen-
trated 20 times by centrifugation at 20,000 × g for 4 h
at 4°C. The concentrated virus was suspended in a
Laemmli SDS sample buffer. As a negative control, we
prepared an env-defective HIV-1 virus (pNLΔenv, pro-
v i d e db yD r .A .A d a c h i )b yu s i n gt h es a m em e t h o da s
for XMRV. A MoMLV-derived retrovirus vector was
produced using the GP293 cell line, with or without
transfection of an amphotropic Env expression vector
(provided by Dr. D. R. Littman). Viral proteins were
separated by 5-20% gradient SDS-PAGE and either
stained with SYPRO Ruby (Bio-Rad, Hercules, CA) or
transferred to a polyvinylidene difluoride membrane
(Wako Pure Chemical Industries, Osaka, Japan) cut into
strips. After blocking with 5% skimmed milk in Tris-
buffered saline (TBS), the strips were incubated with
1:100 diluted donor or patient plasma samples at 4°C
overnight. After washing with TBS containing 0.05%
Tween-20, the strips were incubated with 1:5,000 diluted
horseradish peroxidase (HRP)-conjugated anti-human
IgG Ab (GE Healthcare), and detected by ECL Plus (GE
Healthcare). For endpoint dilutions, a pair of strips was
blotted with 0.8 μg/ml-6.25 ng/ml (1:5,000-1: 640,000)
R187 mAb and detected using 1:5,000 diluted HRP-con-
j u g a t e da n t i - r a tI g G( H + L )s e c o n d a r yA b( J a c k s o n
ImmunoResearch Laboratories, West Grove, PA) for
Gag, or blotted with 8.5 μg/ml-66.4 ng/ml (1:1,000-
1:128,000) anti-Env pAb and detected using 1:2,500
diluted HRP-conjugated anti rabbit IgG (GE Healthcare).
Other immunoblot assays
To produce GST-fused XMRV Gag CA protein, a 789-
bp fragment of the CA gene was amplified using geno-
mic DNA of 293T cells infected with XMRV derived
from 22Rv1 cells, and cloned into the pET-42b(+) vector
(Merck KGaA, Darmstadt, Germany). The GST-CA pro-
tein was purified by a Glutathione-Sepharose 4B column
(GE Healthcare) from bacterial lysate of BL21 Star
(DE3) (Invitrogen) transformed by the GST-fused CA
expression plasmid. To produce His-tagged recombinant
Env SU of xenotropic MLV [19], a PCR-amplified env
SU region was cloned into pcDNA3.1myc/His (Invitro-
gen) followed by subcloning of an env-His DNA frag-
ment into the Bac-to-Bac Baculovirus Expression
System (Invitrogen). The supernatant of Sf9 cells trans-
fected with the bacmid was used for infection of HighF-
ive cells. Recombinant Env proteins collected from the
culture supernatant of infected cells were purified using
a HisTrapHP column (GE Healthcare). In the native-
PAGE, concentrated viruses were suspended with native
sample buffer (Native Sample Buffer; Bio-Rad) and sepa-
rated on a 5-20% gel in a Tris-glycine buffer (25 mM
Tris-Cl, 192 mM glycine, pH 8.4). The subsequent pro-
cedures were for the Ab-screening immunoblot assay.
Detection of viral nucleic acids
For RT-PCR analysis of Ab-positive PC patient samples
(Figure 4A), RNA was isolated from 500 μlo fp l a s m a
using the PureLink Viral RNA/DNA Kit (Invitrogen),
and 8 μlo ft h e1 0μl eluted RNA was reverse-tran-
scribed using Superscript III (Invitrogen) with random
hexamer primers in a total reaction volume of 10 μl. In
the nested PCR assay, 3 μlc D N Ao r1 0 0n gg e n o m i c
DNA of PBMCs was amplified in a 20 μlv o l u m ew i t h
primer pairs GAG-O-F/R and GAG-I-F/R [1] and
AmplyTaq Gold DNA polymerase (Applied Biosystems,
Foster City, CA) for 50 cycles. The PCR cycling condi-
tions were as follows: activation at 95°C for 5 min; then
50 cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for
60 s (30 s in the second-round PCR); with a final exten-
sion at 72°C for 7 min.
To extract genomic DNA from CFS patients, 4 ml of
whole blood in EDTA were centrifuged at 1500 × g for
10 min at room temperature, and 200 μl of the buffy
coat were transferred to a 2 ml tube for DNA purifica-
tion using the QIAamp Blood Mini Kit (Qiagen GmbH,
Hilden, Germany). We divided 180 μlo fe l u t e dD N A
equally into three tubes for analysis at three indepen-
dent laboratories: Department of Research, Japanese Red
Cross Osaka Blood Center, and the Laboratories of Sig-
nal Transduction and Viral Pathogenesis, Institute for
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g e n o m i cD N Ai na5 0μl reaction was performed with
primer pairs GAG-O-F/R and GAG-I-F/R [1] for nested
genomic PCR (data not shown) or 419F and 1154R [2]
and In-For363 and n-Rev536 [6] for single PCR. In the
genomic PCRs, we used PrimeSTAR GXL DNA poly-
merase (Takara Bio, Shiga, Japan) with the following
conditions: activation at 98°C for 2 min; then 45 cycles
of 98°C for 10 s, 63°C for 15 s, and 68°C for 45 s; and a
final step at 68°C for 2 min. For one-step RT-PCR (Fig-
ure 5A), RNAs were purified from 1 ml of 4-day culture
supernatants of P24 PBMCs activated with 10 ng/ml
concanavaline A (J-Oil Mills, Tokyo, Japan) and 100 U/
ml IL-2 (e-Bioscience, San Diego, CA) and maintained
with LNCap-FGC cells or patient plasma using a
QIAamp Ultrasense Virus Kit (Qiagen). One-step RT-
PCR was performed using 15 μlo f6 0μle l u t e dR N A
and a 419F and 1154R primer pair [2] and the following
conditions: reverse transcription at 50°C for 30 min;
activation at 95°C for 15 min; then 45 cycles of 94°C for
30 s, 57°C for 30 s, and 72°C for 1 min; and a final
extension at 72°C for 10 min.
TaqMan real-time PCR tests were performed with 200
ng of genomic DNA, Universal ProbeLibrary, and Fas-
tStart TaqMan Probe Master (Roche, Basel, Switzerland)
in a total reaction volume of 20 μl with a Rotor-Gene Q
thermal cycler (Qiagen). Primer and probe sequences
are as follows: 5’-cctagtggccaccaaacaat-3’ (Env forward),
5’-ggccccaaggtctgtatgta-3’ (Env reverse), and 5’-FAM-
gctccagg-3’ (Env probe, #1 of Universal ProbeLibrary).
The following condition was used: 1 cycle of 95°C for
10 min, and 50 cycles of 95°C for 15 s and 60°C for 45
s.
RNASEL mutation
In patients whose serum tested positive for XMRV
RNA, mutations of RNASEL at amino acid positions 462
[18] and 541 [20] were examined as previously described
[1,20]. PCR-amplified genomic DNA fragments were
sequenced using an ABI PRISM 3100 genetic analyzer
(Applied Biosystems).
Statistics
Non-parametric analysis was performed with the Mann-
Whitney U-test to determine any statistical significance
in the data. A p value of less than 0.05 was considered
to be significant.
Abbreviations
Ab: antibody; ATCC: American Type Culture Collection; CDC: Centers of
Disease Control and Prevention; CFS: chronic fatigue syndrome; EDTA:
ethylenediaminetetraacetic acid; FBS: fetal bovine serum; HBV: hepatitis B
virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; HRP:
horseradish peroxidase; HTLV: human T-lymphotropic virus; IFNγ: interferon-
gamma; MLV: murine leukemia virus; PAGE: polyacrylamide gel
electrophoresis; PBMC: peripheral blood mononuclear cell; PC: prostate
cancer; SDS: sodium dodecyl sulfate; TBS: Tris-buffered saline; XMRV:
xenotropic murine leukemia virus-related virus; WT: wild-type.
Acknowledgements
This work was supported by grant-in-aid “virus-37-2007” from the Blood
Service Headquarters, Japanese Red Cross Society (RAF) and by a grant from
the Bio-oriented Technology Research Advancement Institution (TM). We
thank Dr Robert H. Silverman (Cleveland Clinic, Cleveland, OH) for the
pcDNA3.1-VP62 XMRV clone, Dr Dan R. Littman (New York University, New
York, NY) for pAmpho, and Dr Akio Adachi (Tokushima University,
Tokushima, Japan) for the pNL43 env-deleted mutant. We also thank Ms
Mika Kagura for collecting the blood samples (Osaka City University, Osaka,
Japan), Dr Takayuki Shojima (Kyoto University, Kyoto, Japan) for helping with
the experiments, and our colleagues Mr Hideki Aso and Mr Masaki Yasui
(Department of Blood Products, Osaka Red Cross Blood Center, Osaka,
Japan) for shipping the test blood samples weekly. Finally, we thank the Bio-
oriented Technology Research Advancement Institution for technical advice.
Author details
1Department of Research, Japanese Red Cross Osaka Blood Center, 2-4-43
Morinomiya, Joto-ku, Osaka 536-8505, Japan.
2Laboratory of Signal
Transduction, Institute for Virus Research, Kyoto University, 53 Shogin
Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan.
3Department of Urology,
Nishiwaki Hospital, 652 Shimotoda, Nishsiwaki, Hyogo 677-0043, Japan.
4Department of Health Science, Kansai University of Welfare Science, 3-11-1
Asahigaoka, Kashiwara, Osaka 582-0026, Japan.
5Department of Molecular
Medicine, Mayo Clinic, College of Medicine, Rochester, MN55905, USA.
6Laboratory of Viral Pathogenesis, Center for Human Retrovirus Research,
Institute for Virus Research, Kyoto University, 53 Shogin Kawaharacho, Sakyo-
ku, Kyoto 606-8507, Japan.
7Department of Metabolism, Endocrinology and
Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-
3 Asahicho, Abeno-ku, Osaka 545-8585, Japan.
8Department of Physiology,
Osaka City University Graduate School of Medicine, 1-4-3 Asahicho, Abeno-
ku, Osaka 545-8585, Japan.
9Department of Molecular Virology, Tokyo
Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519,
Japan.
Authors’ contributions
RAF conceived and designed the study, coordinated the collaboration,
carried out the Ab screening and PCR tests, and drafted the manuscript. TM
designed the study, coordinated the collaboration for studies of XRMV
infection in CFS patients and attempted to isolate XMRV. TS recruited PC
patients and carried out immunohistochemical testing of prostate tissues
(data not shown). HK helped in designing the study and recruiting CFS
patients. YI developed the real-time PCR test. ES conducted the Ab
screening and PCR tests of CFS patients and attempted to isolate XMRV. NM
conducted the PCR tests of CFS patients. YN and KY helped in designing the
study and recruiting CFS patients. RS participated in the development of the
real-time PCR test. KY participated in the Ab screening. FH helped in
designing the study and drafting the manuscript. All authors have read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 November 2010 Accepted: 17 March 2011
Published: 17 March 2011
References
1. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K,
Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL: Identification
of a novel gammaretrovirus in prostate tumors of patients homozygous
for R462Q RNASEL variant. PLoS Pathog 2006, 2:e25.
2. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL,
Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH,
Mikovits JA: Detection of an infectious retrovirus, XMRV, in blood cells of
patients with chronic fatigue syndrome. Science 2009, 326:585-589.
3. Zhou A, Hassel BA, Silverman RH: Expression cloning of 2-5A-dependent
RNAase: a uniquely regulated mediator of interferon action. Cell 1993,
72:753-765.
Furuta et al. Retrovirology 2011, 8:20
http://www.retrovirology.com/content/8/1/20
Page 11 of 124. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR: XMRV is present in
malignant prostatic epithelium and is associated with prostate cancer,
especially high-grade tumors. Proc Natl Acad Sci USA 2009,
106:16351-16356.
5. Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher M,
Schlomm T: Prevalence of human gammaretrovirus XMRV in sporadic
prostate cancer. J Clin Virol 2008, 43:277-283.
6. Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, Denner J,
Miller K, Kurth R, Bannert N: Lack of evidence for xenotropic murine
leukemia virus-related virus (XMRV) in German prostate cancer patients.
Retrovirology 2009, 6:92.
7. Lo SC, Pripuzova N, Li B, Komaroff AL, Hung GC, Wang R, Alter HJ:
Detection of MLV-related virus gene sequences in blood of patients
with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad
Sci USA 2010, 107:15874-15879.
8. Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S,
Cleare A: Failure to detect the novel retrovirus XMRV in chronic fatigue
syndrome. PLoS ONE 2010, 5:e8519.
9. Groom HC, Boucherit VC, Makinson K, Randal E, Baptista S, Hagan S,
Gow JW, Mattes FM, Breuer J, Kerr JR, Stoye JP, Bishop KN: Absence of
xenotropic murine leukaemia virus-related virus in UK patients with
chronic fatigue syndrome. Retrovirology 2010, 7:10.
10. van Kuppeveld FJ, de Jong AS, Lanke KH, Verhaegh GW, Melchers WJ,
Swanink CM, Bleijenberg G, Netea MG, Galama JM, van der Meer JW:
Prevalence of xenotropic murine leukaemia virus-related virus in
patients with chronic fatigue syndrome in the Netherlands: retrospective
analysis of samples from an established cohort. BMJ 2010, 340:c1018.
11. Switzer WM, Jia H, Hohn O, Zheng HQ, Tang S, Shankar A, Bannert N,
Simmons G, Hendry RM, Falkenberg VR, Reeves WC, Heneine W: Absence
of evidence of Xenotropic Murine Leukemia Virus-related virus infection
in persons with Chronic Fatigue Syndrome and healthy controls in the
United States. Retrovirology 2010, 7:57.
12. Hong P, Li J, Li Y: Failure to detect Xenotropic murine leukaemia virus-
related virus in Chinese patients with chronic fatigue syndrome. Virol J
2010, 7:224.
13. Enserink M: Chronic fatigue syndrome. Conflicting papers on hold as
XMRV frenzy reaches new heights. Science 2010, 329:18-19.
14. Battini JL, Rasko JE, Miller AD: A human cell-surface receptor for
xenotropic and polytropic murine leukemia viruses: possible role in G
protein-coupled signal transduction. Proc Natl Acad Sci USA 1999,
96:1385-1390.
15. Tailor CS, Nouri A, Lee CG, Kozak C, Kabat D: Cloning and characterization
of a cell surface receptor for xenotropic and polytropic murine leukemia
viruses. Proc Natl Acad Sci USA 1999, 96:927-932.
16. Yang YL, Guo L, Xu S, Holland CA, Kitamura T, Hunter K, Cunningham JM:
Receptors for polytropic and xenotropic mouse leukaemia viruses
encoded by a single gene at Rmc1. Nat Genet 1999, 21:216-219.
17. Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D,
Derisi JL, Chow SA, Silverman RH: An infectious retrovirus susceptible to
an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci
USA 2007, 104:1655-1660.
18. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA,
Catalona WJ, Nupponen N, Carpten JD, Trent JM, Silverman RH, Witte JS:
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer
cases. Nat Genet 2002, 32:581-583.
19. Takeuchi Y, Patience C, Magre S, Weiss RA, Banerjee PT, Le Tissier P,
Stoye JP: Host range and interference studies of three classes of pig
endogenous retrovirus. J Virol 1998, 72:9986-9991.
20. Nakazato H, Suzuki K, Matsui H, Ohtake N, Nakata S, Yamanaka H: Role of
genetic polymorphisms of the RNASEL gene on familial prostate cancer
risk in a Japanese population. Br J Cancer 2003, 89:691-696.
21. Gardner MB, Brown JC, Charman HP, Stephenson JR, Rongey RW,
Hauser DE, Diegmann F, Howard E, Dworsky R, Gilden RV, Huebner RJ: FeLV
epidemiology in Los Angeles cats: Appraisal of detection methods. Int J
Cancer 1977, 19:581-589.
22. Qiu X, Swanson P, Luk KC, Tu B, Villinger F, Das Gupta J, Silverman RH,
Klein EA, Devare S, Schochetman G, Hackett J Jr: Characterization of
antibodies elicited by XMRV infection and development of
immunoassays useful for epidemiologic studies. Retrovirology 2010, 7:68.
23. Tailor CS, Lavillette D, Marin M, Kabat D: Cell surface receptors for
gammaretroviruses. Curr Top Microbiol Immunol 2003, 281:29-106.
24. Robinson MJ, Erlwein OW, Kaye S, Weber J, Cingoz O, Patel A, Walker MM,
Kim WJ, Uiprasertkul M, Coffin JM, McClure MO: Mouse DNA
contamination in human tissue tested for XMRV. Retrovirology 2010, 7:108.
25. Oakes B, Tai AK, Cingöz O, Henefield MH, Levine S, Coffin JM, Huber BT:
Contamination of human DNA samples with mouse DNA can lead to
false detection of XMRV-like sequences. Retrovirology 2010, 7:109.
26. Sato E, Furuta RA, Miyazawa T: An Endogenous Murine Leukemia Viral
Genome Contaminant in a Commercial RT-PCR Kit is Amplified Using
Standard Primers for XMRV. Retrovirology 2010, 7:110.
27. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The
chronic fatigue syndrome - a comprehensive approach to its definition
and study. Annals of Internal Medicine 1994, 121:953-959.
28. Chesebro B, Britt W, Evans L, Wehrly K, Nishio J, Cloyd M: Characterization
of monoclonal antibodies reactive with murine leukemia viruses: use in
analysis of strains of friend MCF and Friend ecotropic murine leukemia
virus. Virology 1983, 127:134-148.
doi:10.1186/1742-4690-8-20
Cite this article as: Furuta et al.: No association of xenotropic murine
leukemia virus-related virus with prostate cancer or chronic fatigue
syndrome in Japan. Retrovirology 2011 8:20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Furuta et al. Retrovirology 2011, 8:20
http://www.retrovirology.com/content/8/1/20
Page 12 of 12